RJA
ATXS

Raymond James & Associates’s Astria Therapeutics ATXS Stock Holding History

Raymond James & Associates’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-12,308
Closed -$103K – 3801
2023
Q2 		$103K Buy
+12,308
New +$142K ﹤0.01% 3627

Other funds holding ATXS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Raymond James & Associates's ATXS Position: Q3 2023 in Review

Raymond James & Associates sold out of Astria Therapeutics (ATXS) in Q3 2023, closing a stake of 12,308 shares — an estimated $103K sold.

Raymond James & Associates first reported a position in ATXS in Q2 2023 and held it in 1 quarter. The position peaked at $103K in Q2 2023. 68 funds tracked by Wall St. Rank hold ATXS as of Q3 2023.

  • Raymond James & Associates reported no remaining Astria Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Raymond James & Associates sold 12,308 Astria Therapeutics shares in Q3 2023, an estimated $103K.
  • Raymond James & Associates first reported a position in Astria Therapeutics in Q2 2023 and held it in 1 quarter.
  • Raymond James & Associates's Astria Therapeutics position peaked at $103K in Q2 2023.
  • 68 funds tracked by Wall St. Rank held Astria Therapeutics as of Q3 2023.

Based on Raymond James & Associates's 13F filing for Q3 2023, filed 24 Oct 2023.